Guardant Health, Inc. $GH Shares Acquired by Assetmark Inc.

Assetmark Inc. increased its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 18,838.6% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 13,257 shares of the company’s stock after acquiring an additional 13,187 shares during the period. Assetmark Inc.’s holdings in Guardant Health were worth $828,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Allworth Financial LP boosted its position in Guardant Health by 358.4% during the second quarter. Allworth Financial LP now owns 706 shares of the company’s stock worth $37,000 after purchasing an additional 552 shares in the last quarter. Sound Income Strategies LLC acquired a new position in shares of Guardant Health during the 3rd quarter worth approximately $38,000. FNY Investment Advisers LLC purchased a new position in shares of Guardant Health during the 2nd quarter valued at approximately $62,000. Smartleaf Asset Management LLC grew its stake in Guardant Health by 162.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,096 shares of the company’s stock valued at $68,000 after acquiring an additional 678 shares during the period. Finally, SBI Securities Co. Ltd. increased its holdings in Guardant Health by 99.4% in the 2nd quarter. SBI Securities Co. Ltd. now owns 1,366 shares of the company’s stock worth $71,000 after acquiring an additional 681 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on GH. Barclays reaffirmed an “overweight” rating and set a $130.00 price objective on shares of Guardant Health in a report on Friday. Leerink Partners raised their price target on shares of Guardant Health from $170.00 to $180.00 and gave the company an “outperform” rating in a research note on Friday. JPMorgan Chase & Co. boosted their price objective on Guardant Health from $120.00 to $130.00 and gave the stock an “overweight” rating in a research note on Friday. UBS Group restated a “buy” rating and issued a $175.00 target price on shares of Guardant Health in a research report on Friday, January 30th. Finally, Mizuho set a $135.00 price target on Guardant Health in a research note on Friday, January 9th. Twenty-one research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Guardant Health currently has an average rating of “Moderate Buy” and an average price target of $117.43.

Insider Activity

In related news, CFO Michael Brian Bell sold 80,362 shares of the company’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $103.14, for a total value of $8,288,536.68. Following the completion of the sale, the chief financial officer owned 28,052 shares of the company’s stock, valued at approximately $2,893,283.28. This represents a 74.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Helmy Eltoukhy sold 90,565 shares of Guardant Health stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $103.82, for a total transaction of $9,402,458.30. Following the transaction, the chief executive officer directly owned 2,047,143 shares in the company, valued at $212,534,386.26. This trade represents a 4.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 434,511 shares of company stock worth $45,580,887. Insiders own 6.10% of the company’s stock.

Guardant Health Price Performance

GH opened at $103.10 on Friday. The firm has a market capitalization of $12.99 billion, a price-to-earnings ratio of -31.15 and a beta of 1.63. The company’s 50 day simple moving average is $106.69 and its two-hundred day simple moving average is $85.94. Guardant Health, Inc. has a 1-year low of $34.88 and a 1-year high of $120.74.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The company had revenue of $281.27 million during the quarter, compared to analysts’ expectations of $269.74 million. During the same period in the previous year, the company posted ($0.62) earnings per share. The business’s revenue was up 39.4% on a year-over-year basis. On average, equities analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Key Stories Impacting Guardant Health

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Multiple brokerages raised price targets and maintained buy/overweight ratings (Leerink to $180, JPMorgan to $130, Wells Fargo to $125, BTIG to $145, Canaccord to $135), signaling analyst confidence in upside from current levels. Analyst Raises Coverage
• Positive Sentiment: Q4 revenue beat and strong growth: Guardant reported $281.3M in Q4 revenue, +39% YoY and above consensus; management issued FY2026 revenue guidance around $1.3B, above Street expectations — a growth signal for core oncology testing. Press Release
• Positive Sentiment: Research coverage expansion: Robert W. Baird initiated coverage, which can broaden institutional interest and trading liquidity. Coverage Start
• Neutral Sentiment: Conference call and transcript available — provides detail on cadence of test volume, reimbursement progress and product roadmap; useful for digging into guidance assumptions. Earnings Transcript
• Neutral Sentiment: Market materials (slide deck, press release) posted for investors to verify segment trends and margin assumptions. Slide Deck / Press Release
• Neutral Sentiment: Short-interest data flagged a “significant increase” entry but shows 0 shares / NaN in the feed — the published data appears inconsistent, so short-interest impact is unclear. Short Interest Note
• Negative Sentiment: EPS miss: GAAP loss of ($0.50) vs. consensus (~($0.43)), which disappointed some investors despite revenue upside and may have pressured the stock near the close. Earnings Reaction
• Negative Sentiment: Management left EPS guidance effectively blank in the release (revenue guidance given but no numeric EPS target), which can create uncertainty around near-term profitability expectations. Guidance Details

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.